BioCentury | May 19, 2020
Management Tracks

Khalil to lead Novartis’ AI Innovation Center

Novartis has enlisted AI-trailblazer Iya Khalil as global head of its AI Innovation Center. The center, for which Novartis AG (NYSE:NVS; SIX:NOVN) is collaborating with Microsoft Corp. (NASDAQ:MSFT), is using AI to speed up the...
BioCentury | Aug 9, 2019
Emerging Company Profile

Owkin: machine learning with privacy protection

To better protect patient privacy in its machine learning-based analyses of real-world data for optimization of drug development and trial design, Owkin’s technology leaves patient data in the originating institutions. Gilles Wainrib, Owkin’s co-founder and...
BC Extra | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...
BioCentury | Mar 23, 2019
Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...
BioCentury | Feb 23, 2019
Tools & Techniques

Modeling now for precision later

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug. While drug companies...
BC Week In Review | Nov 30, 2018
Company News

Merck KGaA, Palantir team up to drive cancer research data collaboration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
BC Extra | Nov 20, 2018
Company News

Merck KGaA, Palantir team up to drive cancer research data sharing and integration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
BC Extra | Oct 4, 2018
Company News

Management tracks: Grail, Nimbus

Cancer detection company Grail Inc. (Menlo Park, Calif.) hired Renée Galá as its first CFO, effective Jan. 3. Gala is SVP and CFO at Theravance Biopharma Inc. (NASDAQ:TBPH). Grail launched in 2016 and has raised...
BC Week In Review | Sep 14, 2018
Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
Items per page:
1 - 10 of 61
BioCentury | May 19, 2020
Management Tracks

Khalil to lead Novartis’ AI Innovation Center

Novartis has enlisted AI-trailblazer Iya Khalil as global head of its AI Innovation Center. The center, for which Novartis AG (NYSE:NVS; SIX:NOVN) is collaborating with Microsoft Corp. (NASDAQ:MSFT), is using AI to speed up the...
BioCentury | Aug 9, 2019
Emerging Company Profile

Owkin: machine learning with privacy protection

To better protect patient privacy in its machine learning-based analyses of real-world data for optimization of drug development and trial design, Owkin’s technology leaves patient data in the originating institutions. Gilles Wainrib, Owkin’s co-founder and...
BC Extra | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...
BioCentury | Mar 23, 2019
Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...
BioCentury | Feb 23, 2019
Tools & Techniques

Modeling now for precision later

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug. While drug companies...
BC Week In Review | Nov 30, 2018
Company News

Merck KGaA, Palantir team up to drive cancer research data collaboration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
BC Extra | Nov 20, 2018
Company News

Merck KGaA, Palantir team up to drive cancer research data sharing and integration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
BC Extra | Oct 4, 2018
Company News

Management tracks: Grail, Nimbus

Cancer detection company Grail Inc. (Menlo Park, Calif.) hired Renée Galá as its first CFO, effective Jan. 3. Gala is SVP and CFO at Theravance Biopharma Inc. (NASDAQ:TBPH). Grail launched in 2016 and has raised...
BC Week In Review | Sep 14, 2018
Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
Items per page:
1 - 10 of 61